Product Description: Upamostat (WX-671) is a serine protease inhibitor. Upamostat is the orally available prodrug of the WX-UK1, which is a urokinase plasminogen activator (uPA) inhibitor.
Applications: Cancer-Kinase/protease
Formula: C32H47N5O6S
References: [1]Heinemann V, et al. Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70./[2]Froriep D, et al. Activation of the anti-cancer agent upamostat by the mARC enzyme system. Xenobiotica. 2013 Sep;43(9):780-4./[3]Park C, et al. HPLC-MS/MS analysis of mesupron and its application to a pharmacokinetic study in rats. J Pharm Biomed Anal. 2018 Feb 20;150:39-42.
CAS Number: 590368-25-5
Molecular Weight: 629.81
Compound Purity: 99.02
Research Area: Cancer
Solubility: DMSO : ≥ 250 mg/mL
Target: PAI-1;Ser/Thr Protease
English
Deutsch
